Why Axsome Therapeutics Stock Cratered in August
Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biotech focused on the development of drugs for central nervous system disorders, had a seriously rough August. The biotech's shares slipped by an eye-popping 47.1% last month, according to data provided by S&P Global Market Intelligence.
Axsome's stock cratered last month for two interrelated reasons:
Image source: Getty Images.
Source Fool.com
